During the last session, ATAI Life Sciences N.V (NASDAQ:ATAI)’s traded shares were 4.06 million, with the beta value of the company hitting 1.44. At the end of the trading day, the stock’s price was $2.66, reflecting an intraday gain of 1.14% or $0.03. The 52-week high for the ATAI share is $2.98, that puts it down -12.03 from that peak though still a striking 61.28% gain since the share price plummeted to a 52-week low of $1.03. The company’s market capitalization is $534.00M, and the average intraday trading volume over the past 10 days was 8.93 million shares, and the average trade volume was 3.31 million shares over the past three months.
ATAI Life Sciences N.V (ATAI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ATAI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.1.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
ATAI Life Sciences N.V (ATAI) registered a 1.14% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.14% in intraday trading to $2.66, hitting a weekly high. The stock’s 5-day price performance is -1.85%, and it has moved by 10.37% in 30 days. Based on these gigs, the overall price performance for the year is 100.00%. The short interest in ATAI Life Sciences N.V (NASDAQ:ATAI) is 10.96 million shares and it means that shorts have 3.83 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 46.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $5 respectively. As a result, ATAI is trading at a discount of -87.97% off the target high and -87.97% off the low.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
In the rating firms’ projections, revenue will increase 338.54% compared to the previous financial year.
As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 273k and 40k respectively. In this case, analysts expect current quarter sales to shrink by -100.00% and then drop by -100.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.62%. While earnings are projected to return 50.00% in 2025, the next five years will return 29.93% per annum.
ATAI Dividends
ATAI Life Sciences N.V is due to release its next quarterly earnings on 2025-May-14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
ATAI Life Sciences N.V insiders own 8.22% of total outstanding shares while institutional holders control 33.40%, with the float percentage being 36.39%. WALLEYE CAPITAL LLC is the largest shareholder of the company, while 105.0 institutions own stock in it. As of 2024-06-30, the company held over 2.76 million shares (or 1.7226% of all shares), a total value of $3.67 million in shares.
The next largest institutional holding, with 2.72 million shares, is of MORGAN STANLEY’s that is approximately 1.6952% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.62 million.
Also, the Mutual Funds coming in first place with the largest holdings of ATAI Life Sciences N.V (ATAI) shares are MORGAN STANLEY INSTITUTIONAL FUND INC-Inception Portfolio and AdvisorShares Trust-AdvisorShares Psychedelics ETF . Data provided on Mar 31, 2025 indicates that MORGAN STANLEY INSTITUTIONAL FUND INC-Inception Portfolio owns about 511.99 shares. This amounts to just over 0.26 percent of the company’s overall shares, with a $1.36 million market value. The same data shows that the other fund manager holds slightly less at 415.76, or about 0.21% of the stock, which is worth about $1.11 million.
